Minoryx
Neurology & CNS Therapeutics · Rare Disease Therapeutics
$55.1Mlatest round · Venture round · May 2022 · 4 yr ago
4backers · Fund+, Inveready
50+team · employees, estimated range
21stories in the press
Overview
Minoryx is focused on the discovery and development of novel treatments for severe, orphan diseases of the central nervous system with high unmet medical need.
Key facts
These are the key facts about Minoryx on Alion as of Nov 13, 2026. The latest round is Venture - Series Unknown of $55.1M, announced in 2022.
- Employees
- 50+Alion company profile, an estimated range
- Total raised
- $55.1MSum of 1 equity round Alion knows
- Latest round
- Venture - Series Unknown · $55.1M · May 30, 2022Press report · minoryx.com
Funding and backers
Total raised
$55.1M
1 round on record
Latest round
$55.1M
Venture round · May 2022 · 4 yr ago
Team
51-200
employees, estimated range
Backers
4
Fund+, Inveready
The money's age
Long since its last round
53 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
2 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
May 31, 2023
Certified Minoryx gains FDA approval to initiate a Phase 3 clinical trial in patients with cerebral Adrenoleukodystrophy · minoryx.com
Nov 9, 2022
Partnership Minoryx and Neuraxpharm announce a strategic alliance to provide a new therapy for rare CNS disease patients in Europe · minoryx.com
May 30, 2022
Raised a round Venture round $55.1M
Apr 2012
Website went live first capture in the Wayback Machine
Tractionpublic signals, read monthly
Web presence
top 2%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | May 2022 | $55.1M | — | minoryx.com |
Backed byfrom the funds' portfolios and accelerator catalogs
Fund+ 
Inveready 
Kurma Partners 
Ysios Capital Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
About Us Proniras Corporation ("Proniras") is a clinical-stage biotechnology company focused on the development of novel small-molecule…
Noema Pharma is a biotech company developing therapies for the most disabling symptoms of orphan conditions of the brain and nervous…
Overview. Ambros Therapeutics, headquartered in San Diego, California, is a clinical-stage biotechnology company focused on the development…
Human cells cannot degrade cholesterol, leading to several chronic and orphan diseases. Repair Biotechnologies’ Cholesterol Degrading…
AMO Pharma is dedicated to making a positive difference for people affected by serious and debilitating diseases, particularly rare or…
On this page Key figures Home > Who we are > Company Our mission is to turn scientific advances in gene therapy into novel treatments for…
Financials
Total raised
$55.1M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2022 | $55.1M | Details |
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Shared investors
News
NEZGLYAL (leriglitazone) receives a positive CHMP opinion for the treatment of cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease
more info
Read more
Report
Leriglitazone Marketing Authorization Application submitted for treatment of cerebral adrenoleukodystrophy has been validated by European Medicines Agency
more info
Read more
Report
Minoryx receives a EUR 26.9m grant within the framework of the European IPCEI Med4Cure project for the continued development of leriglitazone in lethal orphan CNS diseases
more info
Read more
Report
Results from NEXUS interim analysis published in eClinicalMedicine, part of THE LANCET DiscoveryScience
more info
Read more
Report
Minoryx announces dosing of the first patient with leriglitazone in the phase 2a study in Rett syndrome (TREE study)
more info
Read more
Report
Leriglitazone has met the primary endpoint in NEXUS, the pivotal trial for pediatric patients with cerebral Adrenoleukodystrophy
more info
Read more
Report
Leriglitazone halts disease progression in adult patients with early cerebral adrenoleukodystrophy in compassionate-use study published in Brain
more info
Read more
Report
Rare Disease Day 2024 - Call for greater awareness of X-linked adrenoleukodystrophy and cerebral adrenoleukodystrophy - special film launched
more info
Read more
Report
Report
Show more news
How to cite this page
Alion, "Minoryx: key facts", as of Nov 13, 2026. https://alion.io/company/minoryx
These figures are published under a free licence. You may reuse them, including commercially, as long as you credit Alion and link back to this page. CC BY-SA 4.0